A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
For more information please visit: https://classic.clinicaltrials.gov/ct2/show/NCT05608291?term=R3767-ONC-2055&draw=2&rank=1
Kommentare